ISDA

Deposition Date 2012-09-03

Release Date 2012-11-28

Last Version Date 2023-09-13

Entry Detail

PDB ID:

4GWG

Keywords:

OXIDOREDUCTASE

Title:

Crystal Structure Analysis of 6-phosphogluconate dehydrogenase apo-form

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.39 Å

R-Value Free:

0.18

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

P 43 21 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:6-phosphogluconate dehydrogenase, decarboxylating
Gene (Uniprot):PGD
Chain IDs:A
Chain Length:484
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P52209 Pfam ID:PF03446, PF00393 EC:1.1.1.44

Ligand Molecules

MES

Primary Citation

Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.

Hitosugi, T, Zhou, L, Elf, S, Fan, J, Kang, H.B, Seo, J.H, Shan, C, Dai, Q, Zhang, L, Xie, J, Gu, T.L, Jin, P, Aleckovic, M, Leroy, G, Kang, Y, Sudderth, J.A, Deberardinis, R.J, Luan, C.H, Chen, G.Z, Muller, S, Shin, D.M, Owonikoko, T.K, Lonial, S, Arellano, M.L, Khoury, H.J, Khuri, F.R, Lee, B.H, Ye, K, Boggon, T.J, Kang, S, He, C, Chen, J.Show

Cancer Cell 22 585 600 (2012)

PMID: 23153533 DOI: 10.1016/j.ccr.2012.09.020

Abstact

It is unclear how cancer cells coordinate glycolysis and biosynthesis to support rapidly growing tumors. We found that the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), commonly upregulated in human cancers due to loss of TP53, contributes to biosynthesis regulation in part by controlling intracellular levels of its substrate, 3-phosphoglycerate (3-PG), and product, 2-phosphoglycerate (2-PG). 3-PG binds to and inhibits 6-phosphogluconate dehydrogenase in the oxidative pentose phosphate pathway (PPP), while 2-PG activates 3-phosphoglycerate dehydrogenase to provide feedback control of 3-PG levels. Inhibition of PGAM1 by shRNA or a small molecule inhibitor PGMI-004A results in increased 3-PG and decreased 2-PG levels in cancer cells, leading to significantly decreased glycolysis, PPP flux and biosynthesis, as well as attenuated cell proliferation and tumor growth.

Legend

Protein

Chemical

Disease

Primary Citation of related structures